Vir Biotechnology, Inc. logo VIR - Vir Biotechnology, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 10
HOLD 2
SELL 0
STRONG
SELL 0
| PRICE TARGET: $23.50 DETAILS
HIGH: $25.00
LOW: $22.00
MEDIAN: $23.50
CONSENSUS: $23.50
UPSIDE: 116.89%

Stock News

Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer

Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN® dual-masked T-cell engager (TCE), for the treatment of late-line metastatic castration-resistant prostate cancer (mCRPC). VIR-5500 is being co-developed by Astellas Pharma Inc. and Vir Biotechnology through a global strategic collaboration. “Receiving Fast Track designation reflects the potent.

Oct 08, 2026 04:30 AM • businesswire.com
uniQure (NASDAQ:QURE) and Vir Biotechnology (NASDAQ:VIR) Critical Review

uniQure (NASDAQ:QURE) and Vir Biotechnology (NASDAQ:VIR) Critical Review

Vir Biotechnology (NASDAQ: VIR - Get Free Report) and uniQure (NASDAQ: QURE - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership. Volatility and Risk Vir Biotechnology has a beta

Oct 08, 2026 12:15 AM • defenseworld.net
Vir Biotechnology Appoints David Liu as Chief Medical Officer

Vir Biotechnology Appoints David Liu as Chief Medical Officer

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of David Liu, M.D., Ph.D., as Executive Vice President and Chief Medical Officer (CMO), effective October 12, 2026. Dr. Liu will be responsible for leading the clinical development, medical affairs and regulatory affairs functions. “David brings extensive immuno-oncology leadership experience, a strong track record of advancing and securing approvals for innovative cancer therapies and deep expe.

Oct 07, 2026 04:30 AM • businesswire.com
Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD's The Liver Meeting® 2026

Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD's The Liver Meeting® 2026

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of elebsiran and tobevibart for chronic hepatitis delta at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026 in Denver, CO, November 5-9, 2026. Efficacy of elebsiran (VIR-2218) and tobevibart (VIR-3434) in participants with chronic hepatitis delta infection: Patterns of HDV R.

Oct 05, 2026 12:05 PM • businesswire.com
Vir Biotechnology: Astellas Deal Highlights The Platform's Value

Vir Biotechnology: Astellas Deal Highlights The Platform's Value

Vir Biotechnology is now a two-engine company, with major pharma partnerships and a fully enrolled hepatitis delta phase 3 program. Gilead's bulevirtide launch is expanding hepatitis delta diagnosis, indirectly benefiting VIR's upcoming ECLIPSE trials targeting bulevirtide non-responders. The Astellas deal validates VIR's PRO-XTEN platform, providing $335 million in upfront and near-term payments and a premium equity investment.

Sep 29, 2026 01:50 AM • seekingalpha.com
Head-To-Head Comparison: Crescent Biopharma (NASDAQ:CBIO) vs. Vir Biotechnology (NASDAQ:VIR)

Head-To-Head Comparison: Crescent Biopharma (NASDAQ:CBIO) vs. Vir Biotechnology (NASDAQ:VIR)

Vir Biotechnology (NASDAQ: VIR - Get Free Report) and Crescent Biopharma (NASDAQ: CBIO - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends. Valuation and Earnings This table compares Vir

Sep 16, 2026 11:32 PM • defenseworld.net
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, President and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14 at 7:45 a.m. ET in New York City, New York. A live webcast of the fireside chat will be available at https://investors.vir.bio and will be archived for 30 days. About Vir Biotechnology Vir Biotechnology, In.

Aug 31, 2026 12:05 PM • businesswire.com
Vir Biotechnology Q2 Earnings Call Highlights

Vir Biotechnology Q2 Earnings Call Highlights

Vir Biotechnology (NASDAQ: VIR) reported second-quarter 2026 results alongside updates on its chronic hepatitis delta and oncology programs, highlighting completed enrollment in a key hepatitis delta study, plans for multiple data readouts, and expanded development activity for its prostate cancer candidate VIR-5500. The company ended the quarter with approximately $1.01 billion in cash, cash equivalents and

Aug 05, 2026 11:09 PM • defenseworld.net
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the second quarter ended June 30, 2026. “This is a pivotal time for the CHD community, when availability of new therapies could improve awareness, testing and access to care. At EASL, experts emphasized that achieving durable suppression of hepatitis delta virus to undetectable levels is a key predictor of improved clinical outcomes for people with CHD. Our.

Aug 05, 2026 12:05 PM • businesswire.com
Vir Biotechnology Announces Chief Financial Officer Transition

Vir Biotechnology Announces Chief Financial Officer Transition

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed Interim Principal Financial Officer, effective July 23. Jason O'Byrne is leaving the Company to pursue another opportunity and will remain with Vir Biotechnology through August 3 to ensure a smooth transition. The Company has initiated a comprehensive search to identify its next Chief Financial Officer."Brent has deep in.

Jul 24, 2026 04:30 AM • businesswire.com

Price Targets